Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.86)
# 1,555
Out of 5,182 analysts
44
Total ratings
38.24%
Success rate
55.56%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $30 | $5.48 | +447.95% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $9.25 | +94.59% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $9.65 | +55.44% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.68 | +1,030.95% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $12.12 | +147.52% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $4.74 | +364.14% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $5.50 | +336.36% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $15.30 | +716.99% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.04 | +782.35% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $1.98 | +859.60% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.67 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $180.99 | -56.26% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $29.11 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.07 | +714.33% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $4.32 | +41,566.67% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $35.65 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.30 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.43 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.56 | +58,493.75% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.19 | +75,530.25% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $7.92 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $23.96 | +588.65% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.84 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.82 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $30
Current: $5.48
Upside: +447.95%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $9.25
Upside: +94.59%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $9.65
Upside: +55.44%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.68
Upside: +1,030.95%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $12.12
Upside: +147.52%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $4.74
Upside: +364.14%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $5.50
Upside: +336.36%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $15.30
Upside: +716.99%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.04
Upside: +782.35%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $1.98
Upside: +859.60%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.67
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $180.99
Upside: -56.26%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $29.11
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.07
Upside: +714.33%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $4.32
Upside: +41,566.67%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $35.65
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.30
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.43
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.56
Upside: +58,493.75%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.19
Upside: +75,530.25%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $7.92
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $23.96
Upside: +588.65%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.84
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.82
Upside: -